MapLight Therapeutics is a clinical-stage biopharmaceutical company developing targeted treatments for central nervous system disorders using a proprietary discovery platform built on optogenetics and advanced transcriptomics to identify disease-causing neural circuits. The company's lead program is ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist paired with a peripherally acting anticholinergic, in Phase 2 development for schizophrenia and Alzheimer's disease psychosis, addressing significant unmet medical needs where current dopaminergic therapies have poor tolerability and discontinuation rates. MapLight also develops ML-004, a serotonin receptor agonist for autism spectrum disorder, and maintains a pipeline of earlier-stage programs targeting various neuropsychiatric and neurological indications; the company retains global development rights to its programs and plans to commercialize in the US market while seeking partnerships internationally.